Final Highlights from the 2021 J.P. Morgan Healthcare Conference

As the 2021 virtual J.P. Morgan Healthcare Conference wrapped up, there was still news from companies regarding their deals, pipeline and regulatory updates. Here’s a look.

ImmunoGen - ImmunoGen provided an overview of its programs, with a particular focus on submitting its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) before the end of this year for mirvetuximab soravtansine, with hopes of it being approved in early 2022. It is being studied in platinum-resistant ovarian cancer patients with high levels of folate receptor alpha. The submission will be based on data from the Phase III SORAYA clinical trial.